AsedaSciences partners with Chayon Laboratories to enhance drug discovery in South Korea

On March 17, 2025, AsedaSciences, a leading provider of predictive toxicology and safety assessment solutions, announced its new reseller agreement with Chayon Laboratories. This collaboration aims to strengthen drug discovery capabilities in South Korea, allowing scientists access to advanced capabilities earlier in the discovery process. AsedaSciences focuses on integrating non-animal testing methods and machine learning through its innovative 3RnD® platform to improve predictions of toxicity risks, thus supporting safer compound design. Chayon Laboratories is recognized as a premier distributor of drug discovery solutions in Korea, with over 25 years of expertise in the field. This partnership will empower Chayon to market AsedaSciences’ suite of advanced software solutions and predictive modeling tools. By enhancing access to innovative compound screening services, the agreement looks to optimize candidate selection while reducing developmental risks and streamlining safety assessments for researchers and pharmaceutical companies. The collaboration highlights a growing emphasis on predictive analytics within drug discovery workflows. By integrating these modern analytical tools, Chayon Laboratories will provide their clients more informed decision-making capabilities, ultimately accelerating the development of safer and more effective therapeutics. Minah Lee, Managing Director of Chayon, expressed confidence in the partnership, emphasizing their commitment to advancing scientific technologies in drug development. This strategic agreement marks a significant advancement in predictive toxicology and safety assessment capabilities in South Korea. Both companies share a vision of supporting the development of next-generation therapeutics that are safer and more effective for human health and the environment, paving the way for notable progress in the pharmaceutical industry.